West Pharmaceutical Services (WPS) Ratios
West Pharmaceutical Services Ratios
CH:WPS's free cash flow for Q3 2026 was $150.40M. For the 2026 fiscal year, CH:WPS's free cash flow was decreased by $-39.10M and operating cash flow was $189.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.02 | 2.79 | 2.88 | 3.70 | 2.93 |
| Quick Ratio | 2.34 | 2.11 | 2.24 | 2.90 | 2.30 |
| Cash Ratio | 1.21 | 0.88 | 1.27 | 1.72 | 1.28 |
| Solvency Ratio | 0.61 | 0.67 | 0.77 | 0.76 | 0.80 |
| Operating Cash Flow Ratio | 1.15 | 1.19 | 1.16 | 1.39 | 0.98 |
| Short-Term Operating Cash Flow Coverage | 33.25 | 34.76 | 5.79 | 329.09 | 13.21 |
| Net Current Asset Value | $ 884.20M | $ 577.00M | $ 987.90M | $ 987.60M | $ 763.60M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.08 | 0.08 | 0.09 | 0.10 |
| Debt-to-Equity Ratio | 0.13 | 0.11 | 0.11 | 0.12 | 0.14 |
| Debt-to-Capital Ratio | 0.12 | 0.10 | 0.10 | 0.11 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.07 | 0.02 | 0.07 | 0.08 |
| Financial Leverage Ratio | 1.34 | 1.36 | 1.33 | 1.35 | 1.42 |
| Debt Service Coverage Ratio | 27.85 | 29.32 | 5.05 | 70.76 | 14.66 |
| Interest Coverage Ratio | 1029.00 | 205.03 | 80.78 | 100.46 | 89.26 |
| Debt to Market Cap | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest Debt Per Share | 5.77 | 4.22 | 4.28 | 4.38 | 4.49 |
| Net Debt to EBITDA | -0.49 | -0.24 | -0.65 | -0.71 | -0.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 35.89% | 34.65% | 38.38% | 39.47% | 41.45% |
| EBIT Margin | 19.49% | 20.34% | 23.95% | 23.83% | 26.76% |
| EBITDA Margin | 25.07% | 25.71% | 28.60% | 28.01% | 31.08% |
| Operating Profit Margin | 20.09% | 20.56% | 24.09% | 26.46% | 26.80% |
| Pretax Profit Margin | 20.02% | 20.75% | 24.25% | 24.28% | 27.17% |
| Net Profit Margin | 16.06% | 17.03% | 20.11% | 20.30% | 23.38% |
| Continuous Operations Profit Margin | 16.06% | 17.03% | 20.11% | 20.30% | 23.38% |
| Net Income Per EBT | 80.24% | 82.09% | 82.91% | 83.63% | 86.06% |
| EBT Per EBIT | 99.66% | 100.94% | 100.68% | 91.76% | 101.36% |
| Return on Assets (ROA) | 11.56% | 13.52% | 15.50% | 16.20% | 19.97% |
| Return on Equity (ROE) | 15.54% | 18.37% | 20.60% | 21.82% | 28.34% |
| Return on Capital Employed (ROCE) | 17.08% | 19.22% | 22.51% | 24.65% | 27.90% |
| Return on Invested Capital (ROIC) | 13.62% | 15.69% | 17.81% | 20.49% | 23.54% |
| Return on Tangible Assets | 11.89% | 13.97% | 16.01% | 16.78% | 20.81% |
| Earnings Yield | 2.48% | 2.06% | 2.27% | 3.35% | 1.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.35 | 5.24 | 5.76 | 5.69 | 5.79 |
| Payables Turnover | 7.77 | 7.90 | 7.50 | 8.11 | 7.14 |
| Inventory Turnover | 4.44 | 5.01 | 4.18 | 4.21 | 4.38 |
| Fixed Asset Turnover | 1.67 | 1.72 | 1.95 | 2.29 | 2.51 |
| Asset Turnover | 0.72 | 0.79 | 0.77 | 0.80 | 0.85 |
| Working Capital Turnover Ratio | 2.66 | 2.57 | 2.21 | 2.26 | 2.81 |
| Cash Conversion Cycle | 103.44 | 96.30 | 101.93 | 105.85 | 95.25 |
| Days of Sales Outstanding | 68.21 | 69.71 | 63.33 | 64.18 | 63.05 |
| Days of Inventory Outstanding | 82.23 | 72.79 | 87.26 | 86.68 | 83.34 |
| Days of Payables Outstanding | 47.00 | 46.20 | 48.66 | 45.01 | 51.14 |
| Operating Cycle | 150.44 | 142.50 | 150.58 | 150.87 | 146.39 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 10.44 | 8.95 | 10.45 | 9.73 | 7.85 |
| Free Cash Flow Per Share | 6.49 | 3.79 | 5.58 | 5.91 | 4.44 |
| Dividend Paid and CapEx Coverage Ratio | 2.17 | 1.50 | 1.85 | 2.14 | 1.92 |
| Capital Expenditure Coverage Ratio | 2.64 | 1.73 | 2.15 | 2.54 | 2.30 |
| Operating Cash Flow Coverage Ratio | 1.81 | 2.14 | 2.51 | 2.28 | 1.80 |
| Operating Cash Flow to Sales Ratio | 0.25 | 0.23 | 0.26 | 0.25 | 0.21 |
| Free Cash Flow Yield | 2.36% | 1.16% | 1.58% | 2.51% | 0.95% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 40.28 | 48.53 | 44.09 | 29.89 | 52.73 |
| Price-to-Sales (P/S) Ratio | 6.47 | 8.27 | 8.87 | 6.07 | 12.33 |
| Price-to-Book (P/B) Ratio | 6.26 | 8.91 | 9.08 | 6.52 | 14.94 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 42.42 | 86.51 | 63.12 | 39.85 | 105.55 |
| Price-to-Operating Cash Flow Ratio | 26.35 | 36.60 | 33.69 | 24.19 | 59.75 |
| Price-to-Earnings Growth (PEG) Ratio | 33.99 | -3.13 | 31.58 | -2.61 | 0.58 |
| Enterprise Value Multiple | 25.33 | 31.91 | 30.35 | 20.95 | 39.17 |
| Enterprise Value | 19.52B | 23.73B | 25.62B | 16.93B | 34.46B |
| EV to EBITDA | 25.33 | 31.91 | 30.35 | 20.95 | 39.17 |
| EV to Sales | 6.35 | 8.20 | 8.68 | 5.87 | 12.17 |
| EV to Free Cash Flow | 41.63 | 85.86 | 61.80 | 38.54 | 104.23 |
| EV to Operating Cash Flow | 25.86 | 36.32 | 32.99 | 23.39 | 59.00 |
| Tangible Book Value Per Share | 42.30 | 35.14 | 37.11 | 34.40 | 29.60 |
| Shareholders’ Equity Per Share | 43.93 | 36.74 | 38.78 | 36.09 | 31.39 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | 0.18 | 0.17 | 0.16 | 0.14 |
| Revenue Per Share | 42.51 | 39.63 | 39.72 | 38.78 | 38.05 |
| Net Income Per Share | 6.83 | 6.75 | 7.99 | 7.88 | 8.90 |
| Tax Burden | 0.80 | 0.82 | 0.83 | 0.84 | 0.86 |
| Interest Burden | 1.03 | 1.02 | 1.01 | 1.02 | 1.02 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| SG&A to Revenue | 0.13 | 0.12 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Income Quality | 1.53 | 1.33 | 1.31 | 1.24 | 0.88 |
Currency in USD